LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov. 10 2025. A ...

公司财务信息发布安排 - 公司将于2025年11月5日美国东部时间上午9点网络直播其2025年第二季度财务业绩和业务亮点电话会议 [1] - 公司将在电话会议当天市场开盘前发布详细财务业绩的新闻稿 [1] - 电话会议由首席执行官Dave Pacitti和高级副总裁兼首席财务官Scott Galovan主持 [1] 投资者沟通渠道 - 可通过电话即时加入会议，需在会议开始前通过链接注册，或拨打1-646-357-8785或1-800-836-8184由接线员接入 [2] - 电话会议及相关演示文稿的同步网络直播可通过公司官网投资者关系部分获取 [3] - 电话会议结束后两小时内可获取回放，回放将保留一周，也可通过拨打1-646-517-4150或1-888-660-6345并输入密码21545收听回放 [3] 公司业务概况 - 公司是一家医疗技术公司，专注于提供临床卓越的医疗设备解决方案，总部位于佐治亚州阿尔法利塔 [4] - 公司致力于解决当今重要的医疗需求，包括为从医院到家的患者提供营养支持，以及减少阿片类药物使用并帮助患者从手术中恢复 [4] - 公司全球范围内开发、制造和销售其知名品牌，在多个产品类别中占据领先的市场地位 [4] 近期公司动态 - 公司宣布收购私有企业Nexus Medical LLC，以加强其在重症监护领域的营养和药物输送业务 [5] - 公司宣布任命Scott Galovan为高级副总裁兼首席财务官，并任命David Pacitti为董事会成员 [6]

Key Takeaways Tempus AI gained FDA clearance for its RNA-based Tempus xR IVD device aiding drug development. The updated Tempus Pixel earned FDA nod for new T1 and T2 mapping in cardiac MR image analysis. Tempus AI received approval for ECG-Low EF, its second FDA-cleared ECG-AI tool for heart diagnostics.In the first nine months of 2025, Tempus AI Inc. (TEM) achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510(k) ...

BROSSARD, Quebec, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that Dr. Pierre-Luc Charlebois has joined the Corporation’s Advisory Board. Along with fellow members, Dr. Tomas J. Philipson, former vice chairman of the White House Council of Economic Advisers, Mr. Ed Weiner, a seasoned entrepreneur, an ...

VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to report that the United States Patent and Trademark Office (USPTO) has granted patent No. 18/1729,658 entitled, “Contact-Free Breath Analysis Device and Method” to the Company. This patent is centered on innovations made by Cannabix and its dual mode contactless (and traditional mouthpiece) breath capture and analysis technology used ...

公司历史与转型 - 公司由托马斯·爱迪生于1892年创立，拥有超过133年历史，以创新著称 [1] - 公司历史上在多个技术领域进行创新，包括水电、航空、能源电网、风能、医疗保健和材料科学 [2] - 因过度多元化、业务战略失败及涉足金融服务业遭遇重大挫折，股价在2007年至2009年间暴跌超过80% [3] - 原通用电气公司自2021年起分拆为三家独立上市公司：GE Aerospace、GE Vernova和GE HealthCare Technologies [4] 分拆后公司表现 - GE Aerospace在过去五年股价表现最佳，累计上涨727%，GE Vernova上涨417%，GE HealthCare上涨约20% [5] - GE Aerospace是原公司分拆后留存的主体，专注于生产喷气发动机和涡轮螺旋桨发动机等航空部件 [5][7] - GE Aerospace目前市值约为3210亿美元，去年营收超过350亿美元 [6] 近期财务与运营业绩 - 公司第三季度调整后营收增长26%至113亿美元，每股收益增长44%至1.66美元，远超华尔街预期 [8] - 第三季度新订单增长5%至103亿美元，国防收入大幅增长26% [8] - 公司预计今年营收将增长约16%至近410亿美元 [6] 行业与市场状况 - 航空制造业面临瓶颈和供应链问题，这为GE Aerospace创造了有利的运营环境 [5] - 公司股票当前交易价格约为过去盈利的7倍 [6]

Deerfield, Illinois-based Baxter International Inc. (BAX) is a global healthcare technology company specializing in essential hospital and renal-care products like IV solutions, infusion systems, and dialysis therapies. With a market cap of $11.8 billion, its operations span globally, distributing products through direct sales and a network of distributors across many countries. The med-tech giant is expected to announce its fiscal third-quarter earnings before the market opens on Thursday, Oct. 30. Ahead ...

LANDSHUT, Germany, Oct. 26, 2025 (GLOBE NEWSWIRE) -- The latest release of mediCAD® 8 by mediCAD Hectec GmbH marks a new era in intelligent orthopedic and trauma planning. Combining artificial intelligence, automation, and with a completely new user experience, mediCAD® 8 transforms how surgeons prepare and evaluate orthopedic and traumatological procedures - making planning faster, more accurate, and more consistent than ever before. The integrated mediCAD AI technology, represents a significant advancemen ...

人工视觉技术PRIMA的突破性进展 - 世界首创的人工视觉技术PRIMA帮助一位70岁高龄、失明15年的年龄相关性黄斑变性患者重获光明，使其能够再次阅读[2][5][6][11] - 该技术首次证明人工视觉可以恢复患者的功能性中央视力，为失明者带来了希望[10] - 该研究发表于《Nature》期刊，是2025年一项低调但闪亮的科技进展[1][2] PRIMA技术的原理与优势 - 技术原理在于成为光敏细胞的替代物，通过光伏视网膜植入物模拟光子撞击视网膜，刺激幸存的视网膜神经元以恢复视觉[25][27] - 与只能延缓视力丧失的传统疗法不同，PRIMA能够直接逆转并恢复功能性视力[17][24][27] - 整个系统由2mm x 2mm x 30μm的超薄无线植入物和一副特殊眼镜组成，无需外部电线，由捕获图像的红外光束激活[27] PRIMA的临床试验数据 - 临床试验涵盖5个国家、17个临床地点的38名地图样萎缩患者[29] - 最终评估显示，PRIMA系统能让84%的患者恢复功能性中央视力，80%的患者视力实现0.2 logMAR的水平上升[30] - 患者平均视力改善25.5个字母，相当于能看到标准视力测试表下方约5行[30] - 术后部分患者出现排异反应，但95%的症状在2个月内消退，且未对周边自然视力造成显著影响[32] 技术当前局限与未来方向 - 当前系统存在局限性，包括最大视觉敏锐度有待提升，且视觉效果为黑白[35] - 现有植入物包含381个像素，每个像素为100微米平方，用户阅读过程并非快速流畅[35] - 研究团队正在开发下一代植入物和眼镜，旨在实现更小像素、更有效率的视觉性能以及色觉[38] 背后公司Science Corporation的背景 - PRIMA技术由Science Corporation开发，该公司由Neuralink联合创始人Max Hodak于2021年创立[40][41][43] - 公司专注于神经工程和脑机接口技术，旨在治疗视力、认知及行动能力受损的患者[43] - 公司拥有自主的微型医疗芯片制造工厂，可实现从材料、制造到临床实验的全流程自主[44][45] - 公司在2025年4月完成了由Khosla Ventures领投的超1亿美元融资，以加速技术开发和商业化[45] 目标市场与疾病应用 - 技术主要针对年龄相关性黄斑变性的晚期地图样萎缩患者，该患者群体在全球超过500万人[18] - 该技术不仅适用于AMD，对于如色素性视网膜炎等其他感光细胞死亡但视网膜神经元尚存的疾病同样具有应用潜力[33] - 技术被类比为“视力版”人工耳蜗，旨在推动人工视觉成为现实[48][49]

Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" secti ...